Prof. Mohamad Mohty – FDA Breakthrough Therapy Designation for Elranatamab in Relapsed or Refractory Multiple Myeloma

Prof. Mohamed Kharfan Dabaja – Positive Results from Final Progression-Free Survival Analysis of zanubrutinib Compared to ibrutinib in CLL

Prof. He Huang – Non-viral, specifically targeted CAR-T cells, achieve high safety and efficacy in B-NHL

Prof. Mikkael Sekeres – Azacitidine plus venetoclax for myelodysplastic syndromes

Dr. Adi Nagler – Single cell sequencing to chronic lymphocytic leukemia

Prof. Meral Beksac – The recent developments in the field of bispecific T-cell engagers

Prof. Selim Corbacioglu – The importance of veno-occlusive disease prophylaxis

Prof. Paul Richardson – Melflufen for the treatement of relapsed-refractory myeloma

Prof. Mohamad Mohty – New treatments for refractrory acute GVHD

Dr. Eolia Brissot – Approval of maribvir for post-transplant cytomegalovirus infection